POPA ReconA Phase III trial found that a single dose of clesrovimab protected high-risk infants against severe RSV as effectively as monthly…
A Phase III trial found that a single dose of clesrovimab protected high-risk infants against severe RSV as effectively as monthly palivizumab injections, with a similar safety profile. The long-acting antibody could simplify RSV prevention by providing season-long protection with one shot. https://jamanetwork.com/journals/jamapediatrics/fullarticle/2851770
The excerpt is quoted from a public Telegram channel, which owns its text.